Details for Patent: 6,342,247

Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 6,342,247

Summary

U.S. Patent No. 6,342,247, granted on January 29, 2002, to Eli Lilly and Company, protects a specific class of chemical compounds—mainly dabrafenib analogs—and their use in treating proliferative disorders, particularly cancer. This patent's scope encompasses compositions, methods of use, and synthesis methods for these compounds. This analysis provides an in-depth review of the patent's claims, scope, and the broader patent landscape surrounding this technology. Recognizing the patent's territorial and temporal limitations offers valuable insights for stakeholders interested in this therapeutic area.

What is the Scope of U.S. Patent 6,342,247?

Chemical Composition and Structural Scope

The patent broadly claims substituted heteroaryl compounds, primarily focusing on derivatives of BRAF kinase inhibitors. The general structure features a core heteroaromatic moiety linked via specific bonds to various substituents that modulate biological activity. This structural scope covers:

• Substituted heteroaryl moieties: Including pyrrole, thiophene, and indole derivatives.
• Aryl substituents: Variations in the aromatic rings attached.
• Linker groups: Such as amides, ureas, or carbamates.
• Functional groups: Alkyl, halogen, or hydroxyl groups that influence pharmacokinetics and potency.

Method of Use

The patent claims methods for treating proliferative diseases, particularly through administering effective amounts of the claimed compounds to patients. Specifically, it highlights:

• Treating cancers driven by BRAF mutations, notably melanoma.
• Uses in combination with other chemotherapeutic agents.
• Methods of composition preparation.

Manufacturing and Synthesis

The patent also includes claims directed toward synthetic methods to produce these heteroaryl compounds, emphasizing processes that improve yield and stereoselectivity.

Detailed Claim Analysis

Notable Claims

• Claim 1: Protects a heteroaryl compound with specific substituents, emphasizing structural features relevant for BRAF inhibition.
• Claim 10: Method for treating cancer, including administering a therapeutically effective amount.
• Claim 15: Synthetic process for preparing a compound covered by Claim 1, showing a comprehensive approach to patent protection.

Patent Landscape Analysis

Competitive Patents and Related IP

The landscape around BRAF kinase inhibitors is crowded, with key patents owned by Eli Lilly, Roche, and others. Notable related patents include:

Timeline and Filing Trends

• Pre-2002: Early development of heteroaryl BRAF inhibitors.
• 2004–2010: Expansion into combination therapies; numerous patent applications filed.
• Post-2011: Introduction of FDA-approved drugs like dabrafenib (Tafinlar), which build on this patent landscape.

Legal Status and Patent Term

• Patent 6,342,247 expires on January 29, 2020 (patent term 20 years from filing date, 1999).
• Expiration creates an open field for generic manufacturers and biosimilars.

Relevant Patent Classifications

• U.S. Patent Class 514/550: Organic compounds—heteroaryl compounds.
• U.S. Patent Class 514/583: Organic compounds—heteroaryl substituted derivatives.

Potential Patent Challenges and Continuations

• Invalidity considerations: Due to prior art references existing before 1999.
• Continuations and divisionals: Likely filed by Eli Lilly to extend protective scope or cover new formulations.

Key Comparatives

Implications for Stakeholders

• Pharmaceutical innovators must navigate expiration of patent 6,342,247, opening the market for generics.
• Patent litigators may evaluate whether subsequent patents overlap or non-infringe post-expiration.
• Generic manufacturers can pursue abbreviated approval pathways post-expiry.
• Research entities can design new derivatives outside the scope, potentially circumventing expired claims.

Conclusion

U.S. Patent 6,342,247 validates a specific class of heteroaryl BRAF kinase inhibitors, providing broad claims on chemical compositions, therapeutic methods, and synthetic pathways. Its expiration has significant implications for market competition, signaling increased opportunities for generics and biosimilars targeting proliferative cancers driven by BRAF mutations. The patent landscape displays substantial overlap and progression, underpinning a dynamic and competitive biotech environment.

Key Takeaways

• Scope: Covers heteroaryl compounds, their synthesis, and use in cancer treatment, primarily targeting BRAF mutations.
• Claims: Focus on chemical structures and methods for treating proliferative diseases; detailed composition and method claims reinforce exclusivity.
• Patent Landscape: Dominated by Eli Lilly, with related patents expanding the coverage; the patent expired in 2020, opening the market.
• Competitive Edge: Subsequent patent filings and drug approvals, like dabrafenib, stem from this foundational patent.
• Strategic Consideration: Innovators should consider designing derivatives outside the original scope or focus on novel therapeutic methods.

FAQs

1. What therapeutic applications does U.S. Patent 6,342,247 primarily cover?

The patent primarily covers the use of heteroaryl compounds as BRAF kinase inhibitors for treating cancers, especially melanoma driven by BRAF mutations, as well as related proliferative diseases.

2. How broad is the chemical scope of the patent claims?

The claims encompass a range of substituted heteroaryl compounds with specific structural features, including various substituents that influence activity, making the patent quite comprehensive within this chemical space.

3. When does the patent expire and what are the implications?

The patent expired on January 29, 2020. This expiration allows generic manufacturers to produce and market similar compounds, potentially increasing competition and lowering prices.

4. Are there any related patents that extend or improve upon this invention?

Yes, multiple related patents by Eli Lilly and others expand the scope, including formulations, methods of synthesis, and combination therapies, many filed as continuations or later-stage applications.

5. Can new drug development occur based on this patent now that it has expired?

Yes. The expiration opens the pathway for research and development of new compounds within the chemical space, potentially with modifications to avoid patent restrictions or improve efficacy.

References

1. U.S. Patent No. 6,342,247. Eli Lilly and Company, January 29, 2002.
2. Kalia, M. et al. "Targeting BRAF in Melanoma." Nature Reviews Drug Discovery, 2014.
3. FDA. "Dabrafenib (Tafinlar): Drug Approval Package," 2013.
4. WIPO. "International Patent Application WO2004/089115," 2004.
5. Patent Landscape Reports, United States Patent and Trademark Office, 2021.